Tonix Pharmaceuticals Strengthens Board with Commercial Expert Jim Hunter

Tonix Pharmaceuticals (NASDAQ: TNXP), a leading biotechnology firm, has announced the addition of James "Jim" Hunter to its Board of Directors, effective June 12. Hunter, with his extensive background in commercial operations, previously spearheaded the company's commercial subsidiary, Tonix Medicines, and played a pivotal role in its foray into the migraine market. CEO Dr. Seth Lederman highlighted Hunter's invaluable operational and commercial expertise as Tonix gears up for the potential launch of TNX-102 SL, a promising treatment for fibromyalgia, later this year. This move underscores Tonix's commitment to strengthening its leadership team as it advances its pipeline of innovative therapies.

Tonix is at the forefront of developing transformative treatments for pain management and addressing public health challenges. The company is on the verge of submitting a New Drug Application to the FDA for TNX-102 SL, following successful Phase 3 trials for fibromyalgia. Additionally, Tonix is making strides in antiviral research, supported by a significant contract from the U.S. Department of Defense, and continues to expand its portfolio in CNS disorders, immunology, rare diseases, and infectious diseases. With its commercial subsidiary already marketing products for acute migraine, Tonix is poised for significant growth and impact in the biopharmaceutical sector. For more details, visit the full press release at https://ibn.fm/9wBqi.